AbbVie Inc  

(Public, NYSE:ABBV)   Watch this stock  
Find more results for NYSE:ABBV*
-0.03 (-0.05%)
Mar 24 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 65.32 - 66.11
52 week 55.06 - 68.12
Open 65.51
Vol / Avg. 4.06M/7.05M
Mkt cap 104.52B
P/E 17.98
Div/yield 0.64/3.90
EPS 3.65
Shares 1.59B
Beta 1.55
Inst. own 69%
Jan 27, 2017
Q4 2016 AbbVie Inc Earnings Release (Estimated)
Jan 11, 2017
AbbVie Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin 20.47% 23.22%
Operating margin 34.70% 36.60%
EBITD margin - 42.09%
Return on average assets 8.41% 9.99%
Return on average equity 100.48% 138.75%
Employees 30,000 -
CDP Score - 89 D


1 N Waukegan Rd
NORTH CHICAGO, IL 60064-1802
United States - Map
+1-847-9327900 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).

Officers and directors

Richard A. Gonzalez Chairman of the Board, Chief Executive Officer
Age: 63
Bio & Compensation  - Reuters
William J. Chase Executive Vice President, Chief Financial Officer
Age: 49
Bio & Compensation  - Reuters
Michael Severino M.D. Executive Vice President - Research & Development, Chief Scientific Officer
Age: 51
Bio & Compensation  - Reuters
Laura J. Schumacher Executive Vice President, External Affairs, General Counsel and Corporate Secretary
Age: 53
Bio & Compensation  - Reuters
Carlos Alban Executive Vice President - Commercial Operations
Age: 54
Bio & Compensation  - Reuters
Henry O. Gosebruch Executive Vice President, Chief Strategy Officer
Age: 44
Bio & Compensation  - Reuters
Timothy J. Richmond Senior Vice President - Human Resources
Age: 50
Bio & Compensation  - Reuters
Azita Saleki-Gerhardt Ph.D. Senior Vice President - Operations
Age: 53
Bio & Compensation  - Reuters
Robert A. Michael Vice President, Controller
Age: 46
Bio & Compensation  - Reuters
Robert J. Alpern M.D. Independent Director
Age: 65
Bio & Compensation  - Reuters